Back

Failure of Bacillus Calmette-Guerin Therapy in Patients with Bladder Cancer is Characterized by Immune Dysfunction Associated with Activator Protein 1

Garven, A.; Pare, J.-F.; Robins, A.; Vera-Rodriguez, A.; Sampy, R.; Bennett, A.; Nauman, R. W.; Craig, A. W.; Greer, P. A.; Koti, M.; Cotechini, T.; Berman, D. M.; Simpson, A.; Postovit, L.-M.; Siemens, D. R.; Graham, C. H.

2026-05-10 cancer biology
10.64898/2026.05.06.723215 bioRxiv
Show abstract

The standard-of-care for patients with higher-risk non-muscle invasive bladder cancer (NMIBC) after tumour resection is intravesical administration of Bacillus Calmette-Guerin (BCG). While this form of adjuvant immunotherapy has improved recurrence-free and progression-free survival, a large proportion of patients experience recurrences within a year of diagnosis. The reasons for this high rate of early recurrence following BCG therapy remain unclear; however, inadequate activation of systemic immunity may be a contributing factor. To address this, we analysed the transcriptomic and chromatin accessibility profiles of peripheral blood mononuclear cells obtained from patients with NMIBC at single-cell resolution before BCG immunotherapy and after five induction doses of BCG. Monocytes from patients who experienced disease recurrence within a year of initiation of BCG therapy (BCG non-responders) exhibited a pro-inflammatory phenotype consistent with age-related immunosenescence prior to BCG immunotherapy. Moreover, inflammation-associated pathways that were active before initiation of BCG therapy in the BCG non-responders were down-regulated after five instillations of BCG. In contrast, these pathways were quiescent before BCG therapy in patients who remained disease-free for at least a year but were markedly up-regulated after five doses of BCG. Genomic regions with accessible chromatin were enriched in activator protein 1 (AP-1) binding sequences in monocytes from BCG-non-responders prior to BCG therapy. AP-1 is a central regulator of the inflammatory phenotype associated with immunosenescence. Our findings indicate that a pre-existing state of innate immunosenescence underlies early disease recurrence following BCG. Patients unlikely to benefit from BCG may be offered alternative therapies early in their disease journey. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=176 SRC="FIGDIR/small/723215v1_ufig1.gif" ALT="Figure 1"> View larger version (46K): org.highwire.dtl.DTLVardef@1f7c844org.highwire.dtl.DTLVardef@7cea65org.highwire.dtl.DTLVardef@1008d23org.highwire.dtl.DTLVardef@131f973_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 14 journals account for 50% of the predicted probability mass.

1
Clinical Cancer Research
58 papers in training set
Top 0.1%
10.2%
2
Cell Reports
1338 papers in training set
Top 11%
4.4%
3
Frontiers in Immunology
586 papers in training set
Top 2%
4.0%
4
Clinical Epigenetics
53 papers in training set
Top 0.2%
3.7%
5
JCI Insight
241 papers in training set
Top 1%
3.6%
6
Molecular Cancer Research
42 papers in training set
Top 0.1%
3.6%
7
iScience
1063 papers in training set
Top 4%
3.6%
8
Cancers
200 papers in training set
Top 2%
3.1%
9
Scientific Reports
3102 papers in training set
Top 42%
2.9%
10
eLife
5422 papers in training set
Top 31%
2.8%
11
British Journal of Cancer
42 papers in training set
Top 0.5%
2.6%
12
Cancer Research
116 papers in training set
Top 1%
2.5%
13
Cell Reports Medicine
140 papers in training set
Top 3%
2.1%
14
Molecular Oncology
50 papers in training set
Top 0.2%
2.1%
50% of probability mass above
15
PLOS ONE
4510 papers in training set
Top 49%
1.9%
16
Frontiers in Oncology
95 papers in training set
Top 2%
1.9%
17
Nature Communications
4913 papers in training set
Top 51%
1.7%
18
BMC Cancer
52 papers in training set
Top 1%
1.7%
19
EBioMedicine
39 papers in training set
Top 0.5%
1.3%
20
International Journal of Cancer
42 papers in training set
Top 0.8%
1.3%
21
OncoImmunology
22 papers in training set
Top 0.2%
1.2%
22
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.8%
1.2%
23
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 6%
1.2%
24
Genome Medicine
154 papers in training set
Top 6%
1.0%
25
Cells
232 papers in training set
Top 4%
1.0%
26
The EMBO Journal
267 papers in training set
Top 4%
0.9%
27
EMBO Molecular Medicine
85 papers in training set
Top 3%
0.9%
28
G3 Genes|Genomes|Genetics
351 papers in training set
Top 2%
0.9%
29
Molecular Cancer Therapeutics
33 papers in training set
Top 0.6%
0.9%
30
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.2%
0.9%